Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day September 28, 2026 12:00 PM EDT
Company Participants
Joshua Mandel-Brehm – CEO, President & Director
Daniel Tardiff – Chief Scientific Officer
Yuri Maricich – Chief Medical Officer
Mike Graglia
Conference Call Participants
Stephane Auvin
Anupam Rama – JPMorgan Chase & Co, Research Division
Steven Seedhouse – Cantor Fitzgerald & Co., Research Division
Myles Minter – William Blair & Company L.L.C., Research Division
Edward Tenthoff – Piper Sandler & Co., Research Division
Basma Radwan Ibrahim – Leerink Partners LLC, Research Division
Seema Sheoran – Rodman & Renshaw Research
Yun Zhong – Wedbush Securities Inc., Research Division
Presentation
Unknown Attendee
Good afternoon, and welcome to the Camp4 Therapeutics Analyst Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Camp4 website following the conclusion of the event. I’d now like to turn the call over to Josh Mandel-Brehm, Chief Executive Officer at Camp4 Therapeutics. Please go ahead, Josh.
Joshua Mandel-Brehm
CEO, President & Director
Good afternoon, everybody, and thank you for joining us for our first-ever analyst event to discuss CMP-002 for the treatment of SYNGAP1. We are going to be making some forward-looking statements today as part of the discussion, and I encourage everybody to visit our public filings for more information. We have a wonderful agenda for you all today. I’m going to take some time to make some briefly prepared remarks but then you’ll have the opportunity to hear from Beata, a parent and caregiver to their daughter Kasia, about their family’s experience living with SYNGAP1. This will be followed by our CSO, Dan Tardiff; and our CMO, Yuri Maricich, who’re going to review our preclinical data and provide an overview of our ASCEND Phase I/II clinical study. Next, you’re going to hear from the CEO of CURE SYNGAP1, Mike Graglia, who will share his thoughts on the importance of our Phase I/II study and how we collaborated
